MOREPENLABMorepen Laboratories Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals · Infomerics: A (Stable)
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 1.1 this quarter.
Momentum from moving averages, Supertrend and RSI.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
Forensic screen of the latest filings
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹747 Cr | ₹89 Cr | 15.14% | 11.91% | ₹1.62 | 23.5x |
| Q1 FY2027 | ₹570 Cr | ₹56 Cr | 13.01% | 9.89% | ₹1.03 | 16.4x |
| Q4 FY2026 | ₹485 Cr | ₹16 Cr | 3.86% | 3.25% | ₹0.28 | 7.0x |
| Q3 FY2026 | ₹484 Cr | ₹28 Cr | 7.42% | 5.68% | ₹0.50 | 9.2x |
| Q2 FY2026 | ₹412 Cr | ₹41 Cr | 4.72% | 9.93% | ₹0.75 | 11.9x |
| Q1 FY2026 | ₹425 Cr | ₹11 Cr | 3.56% | 2.53% | ₹0.20 | 4.8x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometers, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides OTC and healthcare products, including fever X for fever; Pain X for pain; Fiber-X for constipation; sat isabgol; Acidity X for acidity; Burnol, a first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand name. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.